Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
활용도 Analysis
논문 Analysis
연구자 Analysis
'
Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer' 의 참고문헌
WHO classification of tumours of the digestive system
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer
Trends in Gallbladder Cancer Incidence and Survival in Korea
The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population
The benefit and risk of nivolumab in non-small-cell lung cancer : a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials
Soluble programmed death-ligand 1(sPDL1)and neutrophil-to-lymphocyte ratio(NLR)predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma
Prognostic role of PD-L1 in malignant solid tumors : a meta-analysis
Pembrolizumab(pembro)for advanced biliary adenocarcinoma : results from the KEYNOTE-028(KN028)and KEYNOTE-158(KN158)basket studies
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
PD-L1 expression in human cancers and its association with clinical outcomes
PD-L1 expression in extrahepatic cholangiocarcinoma
PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma
PD-L1 and survival in solid tumors : a meta-analysis
Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma
Incidence and Overall Survival of Biliary Tract Cancers in South Korea from 2006 to 2015: Using the National Health Information Database
Immunotherapy revolutionises non-small-cell lung cancer therapy : results, perspectives and new challenges
Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory:observations based upon 62,896 cases
Identification of unique somatic mutations with functional relevance through genetic characterization of gallbladder cancer(GB ca)
Gallbladder cancer : the basics
Gallbladder cancer : expert consensus statement
Gallbladder cancer : a morphological and molecular update
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Current status of immunotherapy for the treatment of biliary tract cancer
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
Clinical relevance of PD-L1expression in gallbladder cancer : a potential target for therapy
Classification of gallbladder cancer by assessment of CD8(+)TIL and PD-L1 expression
Cancer treatment with anti-PD-1/PD-L1 agents : is PD-L1 expression a biomarker for patient selection
B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells
Avelumab plus axitinib versus sunitinib for advanced renalcell carcinoma
Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer
Association between PD-L1 expression on tumour-infiltrating lymphocytes and overall survival in patients with gastric cancer
Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors : a meta-analysis of randomized clinical trials
AJCC cancer staging manual
'
Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer'
의 유사주제(
